Onderneming XTL Biopharmaceuticals Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
XTLB
IL0010854979
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01-01-99 |
Doron Turgeman
CHM | Chairman | 56 | 30-12-14 |
Daphna Paran
CTO | Chief Tech/Sci/R&D Officer | - | 04-03-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Director/Board Member | 57 | 29-01-20 | |
Director/Board Member | 53 | 01-04-17 | |
Doron Turgeman
CHM | Chairman | 56 | 30-12-14 |
Director/Board Member | 46 | 08-12-14 | |
Director/Board Member | 57 | 01-03-15 | |
Director/Board Member | 63 | 08-12-14 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 514 205 799 | 479 737 353 ( 93,30 %) | 0 | 93,30 % |
Bedrijfsgegevens
XTL Biopharmaceuticals Ltd.
26 Ben-Gurion Street
5112001, Ramat Gan
+972 3 611 6600
http://www.xtlbio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,53% | 54,04 mld. | |
+43,57% | 41,96 mld. | |
-1,14% | 41,92 mld. | |
-7,59% | 28,35 mld. | |
+12,31% | 26,35 mld. | |
-22,39% | 19 mld. | |
+7,92% | 13 mld. | |
+29,16% | 12,28 mld. | |
+25,02% | 12,19 mld. |